Published in J Immunol on September 01, 1985
Complement and systemic lupus erythematosus. Arthritis Res (2002) 1.58
Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome. J Clin Invest (1986) 1.40
Identification of the complement iC3b binding site in the beta 2 integrin CR3 (CD11b/CD18). Proc Natl Acad Sci U S A (1994) 1.39
The role of hypocomplementaemia and low erythrocyte complement receptor type 1 numbers in determining abnormal immune complex clearance in humans. Clin Exp Immunol (1989) 1.24
Loss of complement receptor type 1 (CR1) on ageing of erythrocytes. Studies of proteolytic release of the receptor. Biochem J (1986) 1.16
Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients. J Clin Invest (1993) 1.15
Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis (2005) 1.14
Increased deposition of C3b on red cells with low CR1 and CD55 in a malaria-endemic region of western Kenya: implications for the development of severe anemia. BMC Med (2008) 1.10
Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Haematologica (2013) 1.04
Erythrocytes transfused into patients with SLE and haemolytic anaemia lose complement receptor type 1 from their cell surface. Clin Exp Immunol (1987) 1.01
A transgenic mouse model for studying the clearance of blood-borne pathogens via human complement receptor 1 (CR1). Clin Exp Immunol (2005) 0.99
Elevated serum levels of soluble membrane cofactor protein (CD46, MCP) in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol (1999) 0.97
In vivo handling of soluble complement fixing Ab/dsDNA immune complexes in chimpanzees. J Clin Invest (1989) 0.97
The polymorphism of the C3b/C4b receptor in the normal population and in patients with systemic lupus erythematosus. Clin Exp Immunol (1987) 0.96
Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol (1995) 0.94
The rate of loss of CR1 from ageing erythrocytes in vivo in normal subjects and SLE patients: no correlation with structural or numerical polymorphisms. Clin Exp Immunol (1988) 0.92
Reactivity patterns of anti-phospholipid antibodies in systemic lupus erythematosus sera in relation to erythrocyte binding and complement activation. Clin Exp Immunol (1991) 0.92
Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare. Clin Exp Immunol (2006) 0.92
A CR1 polymorphism associated with constitutive erythrocyte CR1 levels affects binding to C4b but not C3b. Immunology (2003) 0.90
Immune complex binding efficiency of erythrocyte complement receptor 1 (CR1). Clin Exp Immunol (1991) 0.89
Defective complement receptors (CR1 and CR3) on erythrocytes and leukocytes of factor I (C3b-inactivator) deficient patients. Clin Exp Immunol (1986) 0.87
Crystal structure of C5b-6 suggests structural basis for priming assembly of the membrane attack complex. J Biol Chem (2012) 0.86
Antibody CR1-2B11 recognizes a non-polymorphic epitope of human CR1 (CD35). Clin Exp Immunol (2007) 0.86
Erythrocyte complement receptor type 1 (CR1) expression and circulating immune complex (CIC) levels in hydralazine-induced SLE. Clin Exp Immunol (1987) 0.85
Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: a potential therapeutic treatment. Proc Natl Acad Sci U S A (1991) 0.84
Regulation of circulating immune complexes by complement receptor type 1 on erythrocytes in chronic viral liver diseases. Gut (2002) 0.83
Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-accelerating factor. Proc Natl Acad Sci U S A (1989) 0.83
Evaluation of in vivo immune complex formation and complement activation in patients receiving intravenous streptokinase. Clin Exp Immunol (1993) 0.82
C3b receptor (CR1) expression on the polymorphonuclear leukocytes from patients with systemic lupus erythematosus. Clin Exp Immunol (1987) 0.82
Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway. Front Immunol (2016) 0.82
Increased frequency of the long (S) allotype of CR1 (the C3b/C4b receptor, CD35) in patients with systemic lupus erythematosus. Clin Exp Immunol (1992) 0.81
Immune adherence and clearance of hepatitis B surface Ag/Ab complexes is abnormal in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol (1991) 0.81
Peripheral catabolism of CR1 (the C3b receptor, CD35) on erythrocytes from healthy individuals and patients with systemic lupus erythematosus (SLE). Clin Exp Immunol (1992) 0.80
Complement-independent binding of microorganisms to primate erythrocytes in vitro by cross-linked monoclonal antibodies via complement receptor 1. Infect Immun (1995) 0.80
CR1 polymorphism in hydralazine-induced systemic lupus erythematosus: DNA restriction fragment length polymorphism. Clin Exp Immunol (1989) 0.79
Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis. J Biol Chem (2015) 0.79
Immune adherence of nascent hepatitis B surface antigen-antibody complexes in vivo in humans. Clin Exp Immunol (1989) 0.79
In vivo binding of circulating immune complexes by C3b receptors (CR1) of transfused erythrocytes. Ann Rheum Dis (1989) 0.78
An anti-peptide antibody that recognizes a neo-antigen in the CR1 stump remaining on erythrocytes after proteolysis. Clin Exp Immunol (1992) 0.78
Erythrocytes from young but not elderly donors can bind and degrade immune complex- and antibody-bound C3 in vitro. Clin Exp Immunol (1994) 0.78
C3b receptor (CR1) on phagocytic cells from SLE patients: analysis of the defect and familial study. Clin Exp Immunol (1988) 0.78
Exposure to complement-bearing immune complexes enhances the in vitro sequestration of erythrocytes from young but not elderly donors. Clin Exp Immunol (1993) 0.78
Distribution of the HindIII restriction fragment length polymorphism among patients with systemic lupus erythematosus with different concentrations of CR1. Ann Rheum Dis (1991) 0.77
Complement-regulatory protein expression and activation of complement cascade on erythrocytes from patients with rheumatoid arthritis (RA). Clin Exp Immunol (1998) 0.76
Dual role of erythrocyte complement receptor type 1 in immune complex-mediated macrophage stimulation: implications for the pathogenesis of Plasmodium falciparum malaria. Clin Exp Immunol (2011) 0.76
Normal C3b receptor (CR1) genomic polymorphism in patients with insulin-dependent diabetes mellitus (IDDM): is the low erythrocyte CR1 expression an acquired phenomenon? Clin Exp Immunol (1992) 0.76
The relative roles of genetic and environmental factors in the regulation of erythrocyte C3b receptor (ECR1) numbers in normal individuals. Clin Exp Immunol (1987) 0.75
Effect of plasmapheresis on ligand binding capacity and expression of erythrocyte complement receptor type 1 (CR1) of patients with systemic lupus erythematosus (SLE). Clin Exp Immunol (1999) 0.75
The presence of CD55- and/or CD59-deficient erythrocytic populations in patients with rheumatic diseases reflects an immune-mediated bone-marrow derived phenomenon. Med Sci Monit (2014) 0.75
Complement in Lupus Nephritis: New Perspectives. Kidney Dis (Basel) (2015) 0.75
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet (1998) 8.20
Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest (1989) 7.60
Studies on human antibodies. VI. Selective variations in subgroup composition and genetic markers. J Exp Med (1968) 5.72
The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement. J Immunol (1968) 5.40
Combined studies of complement receptor and surface immunoglobulin-bearing cells and sheep erythrocyte rosette-forming cells in normal and leukemic human lymphocytes. J Clin Invest (1973) 5.31
Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9. J Exp Med (1970) 4.92
Two different complement receptors on human lymphocytes. One specific for C3b and one specific for C3b inactivator-cleaved C3b. J Exp Med (1973) 4.46
Reactive lysis: the complement-mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7. J Exp Med (1970) 4.29
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med (1989) 4.19
Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med (1999) 3.88
A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med (2000) 3.65
AIDS--an immunologic reevaluation. N Engl J Med (1984) 3.53
The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). Immunology (1973) 3.41
Analyses of lymphocytes from patients with rheumatoid arthritis and systemic lupus erythematosus. Occurrence of interfering cold-reactive antilymphocyte antibodies. J Clin Invest (1974) 3.24
Conglutinin and immunoconglutinins. Adv Immunol (1967) 3.16
A subclass of human gamma-A-globulins (gamma-A2) which lacks the disulfied bonds linking heavy and light chains. J Exp Med (1968) 2.98
Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation. Immunochemistry (1976) 2.89
Deficiency of C3 inactivator in man. J Immunol (1971) 2.86
Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility. Br Med J (Clin Res Ed) (1983) 2.86
Inactivator of the third component of complement as an inhibitor in the properdin pathway. Proc Natl Acad Sci U S A (1972) 2.84
Studies of the Vi (gamma-2c) subgroup of gamma-globulin. A relationship between concentration and genetic type among normal individuals. J Exp Med (1967) 2.82
Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia. J Clin Invest (1974) 2.81
Expression of Ia-like antigen molecules on human granulocytes during early phases of differentiation. Proc Natl Acad Sci U S A (1977) 2.80
Membrane complement receptors specific for bound fragments of C3. Adv Immunol (1985) 2.80
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology (1990) 2.77
Complement deficiency and disease. Immunol Today (1991) 2.77
Specificity of human lymphocyte complement receptors. J Exp Med (1975) 2.77
Characteristics of isolated erythrocyte complement receptor type one (CR1, C4b-C3b receptor) and CR1-specific antibodies. J Immunol (1981) 2.74
Mannan antigenemia in the diagnosis of invasive Candida infections. J Clin Invest (1976) 2.69
Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity. J Immunol (1982) 2.68
The immunological specificity of a macrophage inhibition factor. Immunology (1970) 2.66
Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis. J Clin Invest (1977) 2.66
Nature of cold-reactive antibodies to lymphocyte surface determinants in systemic lupus erythematosus. Arthritis Rheum (1975) 2.65
Complement studies in membrano-proliferative glomerulonephritis. Clin Exp Immunol (1972) 2.60
Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol (2000) 2.59
The physiological breakdown of the third component of human complement. Mol Immunol (1980) 2.50
Relationship of the functional recovery after hip arthroplasty to the neuroendocrine and inflammatory responses. Br J Anaesth (2001) 2.43
Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol (1996) 2.41
Reaction mechanism of the alternative pathway of complement fixation. Lancet (1973) 2.38
Does pain in fibromyalgia reflect somatization? Arthritis Rheum (2001) 2.37
Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol (1994) 2.36
Identification of a C3bi-specific membrane complement receptor that is expressed on lymphocytes, monocytes, neutrophils, and erythrocytes. J Exp Med (1982) 2.36
Self-propelled Leidenfrost droplets. Phys Rev Lett (2006) 2.36
Complement facilitates early prion pathogenesis. Nat Med (2001) 2.30
Inhibitory effect of non-steroidal anti-inflammatory drugs on mucosal cell proliferation associated with gastric ulcer healing. Lancet (1990) 2.22
Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1). Eur J Immunol (1984) 2.20
Analysis of the different types of leukocyte membrane complement receptors and their interaction with the complement system. J Immunol Methods (1980) 2.17
The purification of specific antibody as F(ab')2 by the pepsin digestion of antigen-antibody precipitates, and its application to immunoglobulin and complement antigens. Immunochemistry (1971) 2.16
p150/95, Third member of the LFA-1/CR3 polypeptide family identified by anti-Leu M5 monoclonal antibody. Eur J Immunol (1985) 2.14
Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med (1995) 2.12
Improved immunoturbidimetric assay for cystatin C. Ann Clin Biochem (2001) 2.09
Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. J Exp Med (1982) 2.04
Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med (1990) 2.03
Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest (1989) 2.01
Hereditary angio-oedema: a review with particular reference to pathogenesis and treatment. Clin Allergy (1971) 2.00
Studies of twins with systemic lupus erythematosus. A review of the literature and presentation of 12 additional sets. Am J Med (1975) 2.00
Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. Nat Med (2001) 1.99
Release of endogenous C3b inactivator from lymphocytes in response to triggering membrane receptors for beta 1H globulin. J Exp Med (1980) 1.96
A sedimentation pattern technique for measuring conglutination: its application to demonstrating immunoconglutinins to C'4. Immunology (1966) 1.95
The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol (1996) 1.94
The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol (1975) 1.93
Role of C3b in the breakdown of C3 in hypocomplementaemic mesangiocapillary glomerulonephritis. Lancet (1973) 1.93
The preparation and properties of alexinated intermediates that react with conglutinin. I. Guinea-pig complement. Immunology (1966) 1.92
Neutrophil and monocyte cell surface p150,95 has iC3b-receptor (CR4) activity resembling CR3. J Clin Invest (1988) 1.92
Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation (1990) 1.91
Three rat monoclonal antibodies to human C3. Immunology (1980) 1.91
Specific concentration of polynucleotide immune complexes in the cryoprecipitates of patients with systemic lupus erythematosus. J Clin Invest (1975) 1.91
The preparation and properties of alexinated intermediates that react with conglutinin. II. Equine, rabbit and human complement. Immunology (1966) 1.88
Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci U S A (2006) 1.87
Isolation of lymphocyte membrane complement receptor type two (the C3d receptor) and preparation of receptor-specific antibody. Proc Natl Acad Sci U S A (1981) 1.86
Imbalances of gamma globulin subgroups and gene defects in patients with primary hypogammaglobulinemia. J Clin Invest (1970) 1.86
Group B streptococci inhibit the chemotactic activity of the fifth component of complement. J Immunol (1988) 1.83
Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest (1991) 1.79
Glycated haemoglobin: an assessment of high capacity liquid chromatographic and immunoassay methods. Ann Clin Biochem (1992) 1.78
Identification and partial characterization of an exercise-induced neutrophil chemotactic factor in bronchial asthma. J Clin Invest (1982) 1.77
Enhanced growth of small bowel in transgenic mice overexpressing bovine growth hormone. Gastroenterology (1993) 1.77
Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology (2001) 1.77
C3bi-binding protein on Candida albicans: temperature-dependent expression and relationship to human complement receptor type 3. Infect Immun (1989) 1.76
Family studies of erythrocyte complement receptor type 1 levels: reduced levels in patients with SLE are acquired, not inherited. Clin Exp Immunol (1985) 1.76
Conglutinin binding polyethylene glycol precipitation assay for immune complexes. Clin Exp Immunol (1979) 1.71
Membrane receptors of mouse leukocytes. II. Sequential expression of membrane receptors and phagocytic capacity during leukocyte differentiation. J Exp Med (1978) 1.69
The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol (1991) 1.68
Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood (2001) 1.65
Hereditary angio-oedema treated with E-aminocaproic acid. Br J Dermatol (1969) 1.64
Identification of Ss protein as murine C4. Nature (1975) 1.63
Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol Res (1993) 1.63
Subclass restriction and polyclonality of the systemic lupus erythematosus marker antibody anti-Sm. J Clin Invest (1985) 1.62